Koji Yoshino Selected Research

Koji Yoshino Research Topics

Disease

28	Melanoma (Melanoma, Malignant) 07/2023 - 06/2016
15	Neoplasms (Cancer) 11/2023 - 01/2010
6	Neoplasm Metastasis (Metastasis) 02/2023 - 01/2017
4	Hemangiosarcoma (Angiosarcoma) 11/2023 - 01/2017
4	Extramammary Paget Disease (Paget Disease, Extramammary) 11/2022 - 06/2016
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2022 - 01/2019
3	Disease Progression 10/2019 - 01/2018
3	Fever (Fevers) 08/2019 - 06/2016
2	Interstitial Lung Diseases (Interstitial Lung Disease) 02/2023 - 01/2018
2	Hemorrhage 12/2018 - 01/2010
2	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 01/2017
2	Massive Hepatic Necrosis 01/2017 - 01/2017
2	Hepatitis 01/2017 - 01/2017
1	Myocarditis (Carditis) 01/2024
1	Skin Neoplasms (Skin Cancer) 11/2023
1	Peripheral Nervous System Diseases (PNS Diseases) 02/2023
1	Basal Cell Carcinoma (Rodent Ulcer) 09/2022
1	Frailty 03/2022
1	Diarrhea 01/2021
1	Schizophrenia (Dementia Praecox) 01/2021
1	Pancytopenia 06/2020
1	Colitis 10/2019
1	Clear Cell Sarcoma 08/2019
1	Sleep Initiation and Maintenance Disorders (Insomnia) 12/2018
1	Ileus 12/2018
1	Orthostatic Hypotension (Postural Hypotension) 12/2018
1	Infections 12/2018
1	Surgical Wound 12/2018
1	Margins of Excision 12/2018
1	Aspiration Pneumonia 12/2018
1	Delirium 12/2018
1	Residual Neoplasm 01/2018
1	Exanthema (Rash) 05/2017
1	Fatigue 01/2017
1	Pneumonia (Pneumonitis) 01/2017
1	Dermatitis 01/2017
1	Pancreatitis 01/2017
1	Thyroiditis 01/2017
1	Thrombocytopenia (Thrombopenia) 01/2017
1	Anemia 01/2017
1	Myalgia 06/2016
1	Hypothyroidism 06/2016
1	Hyperthyroidism 06/2016
1	Breast Neoplasms (Breast Cancer) 01/2010

Drug/Important Bio-Agent (IBA)

17	NivolumabIBA 01/2023 - 06/2016
7	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2017
7	IpilimumabIBA 01/2023 - 11/2017
6	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2018
4	AntibodiesIBA 08/2022 - 01/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 11/2023 - 02/2023
2	taxaneIBA 07/2023 - 02/2023
2	Docetaxel (Taxotere)FDA Link 02/2023 - 06/2016
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 01/2021
2	dabrafenibIBA 12/2021 - 08/2019
2	trametinibIBA 12/2021 - 08/2019
2	C-Reactive ProteinIBA 10/2019 - 08/2019
2	Programmed Cell Death 1 ReceptorIBA 01/2019 - 01/2018
2	pembrolizumabIBA 03/2018 - 01/2018
2	VemurafenibIBA 05/2017 - 01/2017
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2024
1	Methylprednisolone FDA LinkGeneric 01/2024
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2024
1	TroponinIBA 01/2024
1	Plasminogen Activators (Plasminogen Activator)IBA 11/2023
1	Plasminogen Activator Inhibitor 1IBA 11/2023
1	DDTIBA 02/2023
1	5-((glucopyranosyloxy)methyl)uracilIBA 09/2022
1	encorafenibIBA 03/2021
1	binimetinibIBA 03/2021
1	Insulin-Like PeptidesIBA 01/2021
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2021
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 11/2019
1	Interleukin-6 (Interleukin 6)IBA 10/2019
1	1- cyclohexyl- 3- (2- (4- morpholinyl)ethyl)carbodiimideIBA 08/2019
1	Prednisolone (Predate)FDA LinkGeneric 08/2019
1	PlatinumIBA 03/2019
1	LigandsIBA 10/2018
1	HLA Antigens (Human Leukocyte Antigens)IBA 10/2018
1	human ERBB2 proteinIBA 05/2018
1	eribulin FDA Link 01/2018
1	TrabectedinIBA 01/2018
1	Taxoids (Taxanes)IBA 01/2018
1	Therapeutic UsesIBA 01/2017
1	pazopanib FDA Link 01/2017
1	Tyrosine Kinase InhibitorsIBA 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2017
1	Monoclonal AntibodiesIBA 06/2016
1	Fixatives (Pickling Agents)IBA 01/2010

Therapy/Procedure

25	Therapeutics 11/2023 - 01/2017
4	Immunotherapy 01/2023 - 01/2018
4	Drug Therapy (Chemotherapy) 03/2019 - 06/2016
3	Chemoradiotherapy 02/2023 - 01/2018
2	Skin Transplantation (Skin Grafting) 01/2019 - 12/2018
2	Early Ambulation 01/2019 - 12/2018
1	Polypharmacy 03/2022
1	Bed Rest (Bedrest) 01/2019
1	Neoadjuvant Therapy 01/2018
1	Salvage Therapy 01/2018
1	Maintenance Chemotherapy 01/2018
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 06/2016